The Efficacy and Safety of Clonidine Hydrochloride Topical Gel, vs Clonidine Hydrochloride Gel Comparator to Treat Painful Diabetic Neuropathy

NCT ID: NCT02643251

Last Updated: 2017-09-20

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 138 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-12-31
• Study Completion Date: 2016-11-30

Brief Summary

The study will include three (3) phases: Screening Phase, Treatment Phase, and Follow-up Phase. Subjects who qualify to participate will apply study drug to their feet three times daily and will record their daily pain scores using an interactive voice response system (IVRS) during the Treatment Phase for 12 weeks. Approximately 100 adult subjects will be randomized to receive Clonidine Gel or Clonidine Gel Comparator.

Detailed Description

Study CLO-291 is a randomized, double-blind, comparator-controlled, parallel-group, multicenter study of 0.1% clonidine topical gel (Clonidine Gel) for the treatment of pain associated with painful diabetic neuropathy. The study will include three (3) phases: Screening Phase, Treatment Phase, and Follow-up Phase. Subjects who satisfy all eligibility criteria will apply Clonidine Gel Comparator to their feet three times daily and will record their daily pain scores using an interactive voice response system (IVRS). Approximately 100 adult subjects will be randomized to receive Clonidine Gel or Clonidine Gel Comparator during the 12 week Treatment Phase.

Conditions

Painful Diabetic Neuropathy; Diabetic Neuropathy; Neuropathy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

Clonidine Hydrochloride Topical Gel,0.1%

Clonidine Hydrochloride Topical Gel,0.1%

Group Type: EXPERIMENTAL

Clonidine Hydrochloride Topical Gel, 0.1%

Intervention Type: DRUG

Clonidine Gel is supplied as an aqueous gel formulation for topical use.

Clonidine Hydrochloride Gel Comparator

Clonidine Hydrochloride Gel Comparator

Group Type: PLACEBO_COMPARATOR

Clonidine Hydrochloride Gel Comparator

Intervention Type: DRUG

Clonidine Gel Comparator is supplied as an aqueous gel formulation for topical use.

Interventions

Clonidine Hydrochloride Topical Gel, 0.1%

Clonidine Gel is supplied as an aqueous gel formulation for topical use.

Intervention Type: DRUG

Clonidine Hydrochloride Gel Comparator

Clonidine Gel Comparator is supplied as an aqueous gel formulation for topical use.

Intervention Type: DRUG

Other Intervention Names

Clonidine Gel; Clonidine Gel Comparator

Eligibility Criteria

Inclusion Criteria

1. Subject is fluent in English and has provided written informed consent.

2. Subject is an outpatient ≥18 years of age at the time of the Screening Visit.

3. Subject has Type 1 or Type 2 diabetes mellitus with a hemoglobin A1C value < 10% and has been stable on therapy (diet, oral anti-hyperglycemic, and/or insulin) for at least six (6) months prior to the Screening Visit.

4. Subject is a male or non-pregnant, non-lactating female. Females must be practicing an acceptable method of birth control or be surgically sterile or postmenopausal (amenorrhea for ≥12 months). A negative pregnancy test at the Screening and Day 1 visits is required for females of child-bearing potential. Double-barrier methods, hormonal contraceptives, and abstinence are acceptable birth control methods for this study.

5. Subject has chronic pain attributable to a symmetrical stocking distribution neuropathy in the lower extremities for at least six (6) months. Pain should be clearly localized to the area of neuropathy (feet), and subjects should be able to distinguish the target pain from other painful areas and conditions.

6. Subject has an average pain score relevant to the target pain in the feet of ≥4 on an 11 point numerical pain rating scale over the previous 24 hours at the Screening Visit.

7. Subject meets a pre-specified, minimum numerical pain rating scale score following capsaicin skin challenge.

8. Subject must satisfactorily complete Accurate Pain Reporting and Minimizing Placebo Response Training.

9. Subject must have moderate to severe pain during the Screening Run-in Phase.

10. Subjects must be 75 to 110% compliant with application of study drug during the Screening Run-in Phase

11. Subject has been medically stable for at least 30 days prior to the Screening Visit, and in the opinion of the Investigator, is in otherwise good general health based on medical history, physical examination, electrocardiogram, and laboratory evaluation.

Exclusion Criteria

1. Subject has neuropathy secondary to non-diabetic causes in the opinion of the Investigator (e.g., vasculitis, familial neuropathy, alcoholism, pernicious anemia, hepatitis, malignancy, chronic inflammatory demyelinating polyneuropathy [CIDP], human immunodeficiency virus [HIV], medication-induced neuropathy, vitamin B12 deficiency).

2. Subject has a significant neurological disorder or condition that might confound assessment of painful diabetic neuropathy (e.g., stroke with distal neurological deficit, mononeuritis multiplex, lumbar radiculopathy).

3. Subject has a confounding disorder as determined by the Algorithm for Excluding Disorders that Masquerade as Painful Diabetic Neuropathy.

4. Subject has other sustained pain with intensity at or greater than the bilateral neuropathic pain in the feet.

5. Subject is using an implanted medical device (e.g., spinal cord stimulator, intrathecal pump, or peripheral nerve stimulator) for treatment of pain.

6. Subject is hypotensive with a resting diastolic blood pressure <60 mm Hg or a systolic blood pressure <90 mm Hg at the Screening or Day 1 Visit.

7. The subject has recent history (within the past 3 months) or current symptoms of orthostatic hypotension.

8. Subject has a history of foot or toe amputation or an active foot or toe ulcer.

9. Subject has any significant or unstable medical or psychiatric condition that, in the opinion of the Investigator, would interfere with his/her ability to participate in the study.

10. Subject has a history of substance abuse disorder as defined by the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition, within the past year, has current evidence of substance abuse disorder, is receiving medical treatment for drug abuse, or has a positive urine drug screen for a non-prescribed substance of abuse.

11. Subject is receiving or has received within 30 days prior to the Screening Visit any prohibited medications or is anticipated to receive after the start of the trial any new prescription medication for their painful diabetic neuropathy. Subjects may be enrolled if stable on therapy for painful diabetic neuropathy.

12. Subject has symptomatic or severe coronary insufficiency, clinically significant cardiac conduction disturbances, myocardial infarction (within last 12 months), moderate to severe cerebrovascular disease, or severe chronic obstructive pulmonary disease (COPD).

13. Subject has estimated creatinine clearance less than 50 mL/min (Cockcroft Gault) at the Screening Visit.

14. Subject has serum alanine transaminase (ALT) or aspartate transaminase (AST) >3.0 times the upper limit of normal or total bilirubin concentrations >2.0 times the upper limit of normal at the Screening Visit.

15. Subject has received an investigational drug within 30 days prior to the Screening Visit.

16. Subject has been treated previously with clonidine topical gel or participated in a clonidine topical gel clinical study, including Study CLO 290.

17. Subject is currently taking or has taken clonidine (any formulation) over the past 4 weeks.

18. Subject has known hypersensitivity or intolerance to clonidine.

19. Subject is receiving or has received ≤7 days prior to the start of the Screening Phase "alternative medicine" products or treatments (e.g., acupuncture, naturopathy, homeopathy, etc.) for management of pain.

20. Subject has a history of malignancy within the past 5 years except for successfully treated non-metastatic basal cell or squamous cell carcinomas of the skin and/or localized carcinoma in situ of the cervix.

21. Subject is planning to have surgery during the course of the study.

22. Subject has significant skin changes on physical examination associated with either pedal edema or venous stasis disease.

23. Subject has any dermatologic condition of the lower extremities that could affect study drug absorption

24. Subject has current symptoms of depression with a Beck Depression Inventory II (BDI II) score >19 at the Screening Visit.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

BioDelivery Sciences International

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Aziz Shaibani, MD

Role: PRINCIPAL_INVESTIGATOR

Nerve and Muscule Center of Texas

Locations

Glendale, Arizona, United States

Phoenix, Arizona, United States

Phoenix, Arizona, United States

Anaheim, California, United States

Norco, California, United States

Sacramento, California, United States

Santa Monica, California, United States

Tustin, California, United States

Fort Myers, Florida, United States

Ocala, Florida, United States

Orlando, Florida, United States

Tampa, Florida, United States

West Palm Beach, Florida, United States

Blackfoot, Idaho, United States

Boise, Idaho, United States

Belleville, Illinois, United States

Blue Island, Illinois, United States

Chicago, Illinois, United States

Hazelwood, Missouri, United States

Cleveland, Ohio, United States

Spartanburg, South Carolina, United States

Knoxville, Tennessee, United States

Houston, Texas, United States

San Antonio, Texas, United States

San Antonio, Texas, United States

Countries

United States

Other Identifiers

CLO-291

Identifier Type: -

Identifier Source: org_study_id